Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

被引：0
|
作者：
马润芝 [1 ]
机构：
[1] State Key Lab, Hematol Experiment, Natl Clin Blood Dis Res Center, Instit Hemat & Blood Dis Hosp, CAMS & PUMC
来源：
China Medical Abstracts(Internal Medicine) | 2021年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R733.71 [急性白血病];
学科分类号：
100214 ;
摘要：
Objective To investigate the long term efficacy and side effects of a donor-derived CD19 chimeric antigen receptor (CAR) T-cell (HI19α-4-1BB-ζCAR-T) therapy in the treatment of patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)
引用
收藏
页码：228 / 229
页数：2
相关论文
共 50 条
  • [1] Donor-Derived Second Generation of CD19 CAR-T Cell Therapy for Relapsed B-Cell Acute Lymphoblastic Leukemia after Allogenic Stem Cell Transplantation
    Zhang, Rongli
    He, Yi
    Yang, Donglin
    Wang, Ying
    Feng, Sizhou
    Wang, Jianxiang
    Han, Ming-Zhe
    BLOOD, 2018, 132
  • [2] DONOR-DERIVED CAR-T CELLS FOR THE TREATMENT OF RELAPSED ACUTE B-LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Deng, Lei
    Yu, Xiaolin
    Song, Xiaocheng
    Guan, Rui
    Shao, Yan
    Li, Wenjun
    Zhou, Fang
    BONE MARROW TRANSPLANTATION, 2024, 59 : 47 - 48
  • [3] Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation
    Cao, Xing-Yu
    Li, Jing-Jing
    Lu, Pei-Hua
    Liu, Kai-Yan
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (03) : 315 - 329
  • [4] Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation
    Xing-yu Cao
    Jing-jing Li
    Pei-hua Lu
    Kai-yan Liu
    International Journal of Hematology, 2022, 116 : 315 - 329
  • [5] Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation
    Liu, Shuangyou
    Deng, Biping
    Yin, Zhichao
    Lin, Yuehui
    An, Lihong
    Liu, Dan
    Pan, Jing
    Yu, Xinjian
    Chen, Bingzhen
    Wu, Tong
    Chang, Alex H.
    Tong, Chunrong
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (06) : 671 - 679
  • [6] CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia
    Liu, Jun
    Zhang, Xi
    Zhong, Jiang F.
    Zhang, Cheng
    IMMUNOTHERAPY, 2017, 9 (13) : 1115 - 1125
  • [7] Efficacy and risk of donor-derived CAR-T treatment of relapsed B-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation
    Deng, Lei
    Yu, Xiaolin
    Song, Xiaocheng
    Guan, Rui
    Li, Wenjun
    Hou, Yixi
    Shao, Yan
    Zhao, Yuerong
    Wang, Jing
    Liu, Yue
    Xiao, Qianqian
    Xin, Bo
    Zhou, Fang
    CYTOTHERAPY, 2024, 26 (11) : 1301 - 1307
  • [8] Donor-derived stem cell infusion for sustained pancytopenia after CD19 CAR-T therapy for relapsed patients post allogeneic stem cell transplantation
    Li, Yingying
    Li, Yixue
    Zhang, Mingming
    Zhao, Houli
    Zhu, Miaoyong
    Huang, He
    Hu, Yongxian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (01) : 94 - 101
  • [9] Allogeneic Donor-Derived CD19-Chimeric Antigen Receptor (CAR) T Cells for Relapsed B-Cell Malignancies After Hematopoietic Stem Cell Transplantation
    Muhsen, Ibrahim N.
    Cruz, Helton
    Zhang, Huimin
    Thakkar, Sachin G.
    Grilley, Bambi
    Gee, Adrian P.
    Heslop, Helen E.
    Brenner, Malcolm K.
    Ramos, Carlos A.
    MOLECULAR THERAPY, 2022, 30 (04) : 227 - 227
  • [10] ALLOGENEIC DONOR-DERIVED CD19-CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR RELAPSED B-CELL MALIGNANCIES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Muhsen, I. N.
    Cruz, H.
    Zhang, H.
    Thakkar, S. G.
    Grilley, B.
    Gee, A. P.
    Heslop, H.
    Brenner, M.
    Ramos, C. A.
    CYTOTHERAPY, 2022, 24 (05) : S27 - S28
12345